Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 147,601
  • Shares Outstanding, K 53,869
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,730 K
  • 60-Month Beta 3.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.20
  • Number of Estimates 5
  • High Estimate -0.14
  • Low Estimate -0.26
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.99 +28.64%
on 01/31/20
3.09 -17.15%
on 02/20/20
+0.49 (+23.67%)
since 01/27/20
3-Month
1.08 +137.04%
on 12/04/19
3.09 -17.15%
on 02/20/20
+1.36 (+113.33%)
since 11/27/19
52-Week
0.77 +232.47%
on 07/24/19
5.40 -52.59%
on 04/29/19
-1.06 (-29.28%)
since 02/27/19

Most Recent Stories

More News
Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it has reached...

MRNS : 2.56 (-6.57%)
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that management...

MRNS : 2.56 (-6.57%)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders,...

MRNS : 2.56 (-6.57%)
Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the upcoming...

MRNS : 2.56 (-6.57%)
Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), (Nasdaq: MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric...

JPM : 121.37 (-4.16%)
MRNS : 2.56 (-6.57%)
Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%

Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.

IRWD : 11.90 (+7.50%)
MRNS : 2.56 (-6.57%)
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options

Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

MRNS : 2.56 (-6.57%)
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders,...

MRNS : 2.56 (-6.57%)
Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), ("Marinus" or the "Company") today announced the closing of an underwritten public offering of 32,200,000 shares of common stock at a public offering price...

LTS : 3.49 (-0.29%)
MRNS : 2.56 (-6.57%)
Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric...

MRNS : 2.56 (-6.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade MRNS with:

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

2nd Resistance Point 2.86
1st Resistance Point 2.71
Last Price 2.56
1st Support Level 2.47
2nd Support Level 2.38

See More

52-Week High 5.40
Fibonacci 61.8% 3.63
Fibonacci 50% 3.09
Last Price 2.56
Fibonacci 38.2% 2.54
52-Week Low 0.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar